| Autor: |
Gaughran, Gregory, Aggarwal, Neha, Shadbolt, Bruce, Stuart-Harris, Robin |
| Zdroj: |
Breast Cancer Management; September 2020, Vol. 9 Issue: 4 |
| Abstrakt: |
Background:Cancer antigen 15.3 (CA15.3) is a commonly used tumor marker (TM) in metastatic breast cancer (MBC) but may not be raised. We assessed CA15.3, carcinoembryonic antigen (CEA), cancer antigen 125 (CA-125) and cancer antigen 19.9 in 193 MBC patients at diagnosis and follow-up. Materials & methods:This TM panel was measured approximately 3 monthly. Median follow-up was 29.3 months. Results:At diagnosis, the following TMs were raised: CA15.3 63.2%, CEA 37.3%, CA-125 45.0% and cancer antigen 19.9 17.3%. CA15.3 became raised later in 28/71. Raised TMs were less common in HER2+ tumors. CA-125 was frequently raised in triple negative tumors and was associated with pleural metastases. More raised TMs correlated with more sites of metastases and shorter survival. Conclusion:CEA and CA-125 showed benefit over CA15.3 alone in MBC and all three should be considered in MBC. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
